Tesamorelin
FDA ApprovedStrong EvidenceTesamorelin Acetate
The only FDA-approved GHRH analog — approved for HIV-associated lipodystrophy, and studied for visceral fat reduction and cognitive health.
Half-Life
~26 minutes
Molecular Weight
5135.7 g/mol
Tesamorelin is a synthetic GHRH analog distinguished by an N-terminal trans-3-hexenoic acid modification that extends its half-life and metabolic stability. It is FDA-approved (as Egrifta) for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy — a condition causing abnormal fat redistribution from antiretroviral therapy. Beyond this approved indication, tesamorelin has been investigated for visceral adiposity in non-HIV populations and, notably, for cognitive decline in older adults with mild cognitive impairment. It represents the gold standard among GHRH analogs due to its clinical validation.
Also Known As
Amino Acid Sequence
Trans-3-hexenoic acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Reconstitution
Reconstitute with provided diluent. Each vial typically contains 1 mg tesamorelin.
Open Reconstitution Calculator →